\ fltfff,{ffiq gNQq tc[|-i, qt4qeqr mqi6loTr$.S.rry.fr,/zozt /g 1 / sfr, 1. wrw o-A-ffi, q.q I 2. srrw sTDETdr, fr'fu-ffir q-6rfuqrd-q, q.s I 3. wrtffi gw ftfoer qq wNQq srffi, q.s t 4, sirftI frfuf, $fq sE 5q q$f,ld orftro, q.q I fiqrd, ft{io 2T/os/zozt frqq:- ffii€Tq .** gl: r{rnfra qhilq\ 1rq 'pft s-6-r"it d TTfi d G.non,. Sequencingd ffil frt r4q{:- dqra-qrfi-{r-{ Tr ffi'.,/oTl-$.S.gq'.fr./2ozo/zos3 fiqrd ft-{ier $/12/2020 frEqro,In a-g. t fu reer t otfr.s-re fiqt-rm-ivt. t-g q-f,{€rTt cil-{a {{{flI @t qrffi f{ffi d orgux EfrRqd fr,qr qr q6T C' \rq 3nq Rrio iltr qG 30,ee,5oo t-qer dT{ q-d(, q-d ar$q qd-q, oo q{ t siBo sq d qk. itrl 45 q{ t 3rB6 Co-morbid qfu qfrqfu-a t t qa ter rqT fu 6ft-rq q-m-wil d otBs ffi-iq{ d z e)q flw 6ri ' d qyqrd fi tnifr--s-1e q,-T gq: {rm-quT ggn t I qd lgqq B fu tt !-fl"fr t @HqT qlrrrs d qqw i E.earq E3rT d I sARS coYZA *iqrfuo r$ q-f,rfr fr qrci{fl d E-f,fq, Cifr-6 6)s, qarTq enft w 3Tqq.q tg FruqrR frdaT Rr qr-i t'- . o}fue-rg d wrtkr gdq-in.q"r A qrnfuf, tro-{"it gq r.fr{ Iro-{"il d T{i Genome sequencing tg nRil fuq qrt t o gs fu qltfus ffiivrq srq qfrnrqt ti nvsanr d aeryr M ti qq o'Ifus q,1 qra & q1{r fuqr qr} 1'q um qrr qififtq qr} qri qr l{Efuil e-q Ehl qfrffi fuqr qri r . Tf,i'T riT6,T o1 6Tffi Td q R\ -rq Frffi o-l q?rl fr=Trgirn gfrkqd fuqT sd'- o r{il q-,r6rT qfi o-rffi qfrTfs-a qrrq q-trrsrq (frfu-trT erfffiZd-q t=ffiRrq-q/v<rq qq{) gm fr.fi{ fu-e lruttComponent)q-6=Eq fu-ql qdI o Genome Sequencing i-g \-f Oro-pharyngeal i-ell Vfi Naso-pharyngeal Swab cF-l Tiq-6tT, 3 mlvrMtubeti en$qfr.qq.3Tri 6 prffi qtT slEll'o€ gf \-f,hd o1 qrit o sqq qRTfu G-g m. 4 gq s fr s-Ffd 3rd'ffiq utM d em.fr.fr.qfr.Gil( .ilrq d fr\ vrM tube t ft\ qq e-qd fr * r mlsrqd, em.fr.ft.rft.3TR qfrrr:TrdlC arT grf, aliquot O-g -800 C W Deep Freezer ti fr."r" fuqT .ilt t efn.0.ft.el-{. \flfq ffi-d m-frfr-q eni w gu durft-o 1 61frq"6 C G.no*. Sequencing tg ftrcrfuT RGSL t Qqd-aw Sfur o-r Dry rce t oisrc +{ gBR-dd o-ri g\ riqr qnr eir t o r1T{d q1.1-m-R ilq qlaT tg ftrcIfuT Regional Genome Sequencing Laboratories (RGSL) O-T fr-f,i"r frET5qlIq t- I NCDC, Delhi - Division of Bio-technology, Epidemiology & Central Surveillance Unit (Estimated Sequencing Capacity - 3000 per month) Eastern part of MP 2, ICMR - National Institue of Virology (NM), Pune DBT National Center from Cell Science, Pune (Estimated Sequencing Capacity - 1200 per month) Western part of MP
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
\ fltfff,{ffiq gNQq tc[|-i,qt4qeqr
mqi6loTr$.S.rry.fr,/zozt /g 1 /sfr,
1. wrw o-A-ffi, q.q I
2. srrw sTDETdr, fr'fu-ffir q-6rfuqrd-q, q.s I
3. wrtffi gw ftfoer qq wNQq srffi, q.s t
4, sirftI frfuf, $fq sE 5q q$f,ld orftro, q.q I
fiqrd, ft{io 2T/os/zozt
frqq:- ffii€Tq .** gl: r{rnfra qhilq\ 1rq 'pft s-6-r"it d TTfi d G.non,.
frEqro,In a-g. t fu reer t otfr.s-re fiqt-rm-ivt. t-g q-f,{€rTt cil-{a {{{flI @t
qrffi f{ffi d orgux EfrRqd fr,qr qr q6T C' \rq 3nq Rrio iltr qG 30,ee,5oo t-qer
dT{ q-d(, q-d ar$q qd-q, oo q{ t siBo sq d qk. itrl 45 q{ t 3rB6 Co-morbid
qfu qfrqfu-a t t qa ter rqT fu 6ft-rq q-m-wil d otBs ffi-iq{ d z e)q flw 6ri '
d qyqrd fi tnifr--s-1e q,-T gq: {rm-quT ggn t I qd lgqq B fu tt !-fl"fr t @HqT qlrrrs
d qqw i E.earq E3rT d I sARS coYZA *iqrfuo r$ q-f,rfr fr qrci{fl d E-f,fq, Cifr-66)s, qarTq enft w 3Tqq.q tg FruqrR frdaT Rr qr-i t'-. o}fue-rg d wrtkr gdq-in.q"r A qrnfuf, tro-{"it gq r.fr{ Iro-{"il d T{i Genome
sequencing tg nRil fuq qrt t
o gs fu qltfus ffiivrq srq qfrnrqt ti nvsanr d aeryr M ti qq o'Ifus q,1
qra & q1{r fuqr qr} 1'q um qrr qififtq qr} qri qr l{Efuil e-q Ehl qfrffi fuqrqri
3 mlvrMtubeti en$qfr.qq.3Tri 6 prffi qtT slEll'o€ gf \-f,hd o1 qrito sqq qRTfu G-g m. 4 gq s fr s-Ffd 3rd'ffiq utM d em.fr.fr.qfr.Gil( .ilrq d fr\
vrM tube t ft\ qq e-qd fr * r mlsrqd, em.fr.ft.rft.3TR qfrrr:TrdlC arT grf,aliquot O-g -800 C W Deep Freezer ti fr."r" fuqT .ilt t efn.0.ft.el-{. \flfq ffi-dm-frfr-q eni w gu durft-o 1 61frq"6 C G.no*. Sequencing tg ftrcrfuT RGSL
t Qqd-aw Sfur o-r Dry rce t oisrc +{ gBR-dd o-ri g\ riqr qnr eir t
ig-i gi q-6 3r.ira 3iltlYrm t fu qrso ii ilT{s d v-on s mieT fr flrlEI ffid q'-{i tg"fcnftq; g{erq" (Genomic Surveillance) e1 uTt I {g tg Indian SARS-co v-2 Genomics consortium
GNSACOG) Arsr Tf,n qfr d-q q'{ qlq-{s d qqorq, difro ots, qellq erR w elqqq frtql
rrf,-qfrsrd rqt cenome Sequencing d fuq nfud fug qri t
k{i6 og frsqt - zz ftmqq 2020 d qEq qrgf, sTrt t-fr 3ffiq qrfr ffi o}fus-rg d
65q sfuiR-f, iii \q 3TR.4.fi.fi.3TR. qiq qf-fiEq dt, a rxi c"ro-e S-equencins t-g tdqrt t gqw sral atrq 1fud qrffif a .,1iq q{i qr{fi.\FI.3TR. .rr$g-dr{q 3rgfiR T-ryr{qd k{i6 d s t - 10 t ffi A @ fuq *O gu 3Tn.A.ft'fi'3rx' qiq trSfuq qrn qri
E1r{T f,FF-td Yr'J{i $?td."{-{ 3lffi 6T qftTfr ft;ql wz) t
r i. trte-{ qr* E} q{ q{ ftqffi{f, ** ,n-orna ff{rdt cajn srrw sl5qrft-6 'Tirl-mJ" of fuffiqi iilri 1'q rtqd k{16 s s t ro i k+s d mq rqftffi eil{.$.qq.cr{lY. .n{€-d{r{q 31"Jqn
s{a&r aeTq tsffiT dri .rq d65ra eTn.E.ff.fr.orx. qqfu t iiliq ?F-{i dt qq-sdqT fi qr} t
)w^-- #"Mgr*r*,It has been reported that a distinct Phylogenetic cluster of SARs-CoV-2 variant has
been detected. This SARS-CoV-2 variant-is spreading & growing rapidly in UniteclKingdorn. It has also been reportecl that this variant has an unusually large number qfgenetic changes particularly in the spike protein. This development calls for enhanceclepidemiological surveillance, enhanced containment & other measures to effectivelytackle the challenge.
2. As you are aware, India has been seeing a sustainecl clecline in the number of fi'eshCovid-l9 cases for over 2 t/z months now, accompaniecl by a decline in the number oldeaths. In this scenArio, any interjection of a SARS-CoV-2 variant virus throgghpassengers with air travel history cor"rld pose critical risks for pandemic managen:ent inInclia.
3' In this connection, based otr the inputs reoeived tlom the .loint Monitoring Group(.IMG) headed by the Director General of Health services (DGHS) and the Vaccine I'askForce headed by the Principal Scientific Advisor and Member (Healrh), NITI, thefollorving is proposed:-
1. Immediate steps
(i) As a $leasure of abundant caution, passengers arriving ti.orn U,K in allinternational flights (flights in transit) ihould be subjecte-d ro mandatory R1'PCR tests on arrival at the airporls concerned.
Governnrent of lndiaDe partment of Health and Family We lfar*
Ministry of Health ancl Fanrily Welfare
D.O No. Z-2 I 0201 l_6i2020-PH2l't December 2020
a' Those rvho are found positive on arrival must be sent for institutionalquarantine/isolation set up by the State/UT Governments, in collaboratiolwith the States/UTs concerned.
b. Those who are found negative in RT-PCR tests should be advised to isolatethemselves at home for seven days, to be medically monitorecl by theStatesfuTs concerned.
c. I{elevant inforrnation in this regard may be prominently clisplayed in arrivalarea, waiting area of thc airports.
(ii) Kindly coordinate with the airport authorities in your jurisdiction to urgentlyset r"tp adequate number of help desks, manned b1, State/UT perseinnel at theairports to facilitate this exercise,
(iii) Adequate arrangements for passengers rvaiting tbr their RT PCR test resultsmay also be made at the airports in corrjunction with the airport authorities.
2. SFrveillance and follow,un meqsures
(i) The surveillance teams should be given a clear mandate and action plan forphysical monitoring of all those who have tested negative in the RT-PCR testand are under home isolation. The tean:s should ensure their proper isolation,monitoring of paranteters and ensure follow up RT-PCR test after 7 days ofdisembarkation.
(ii) In case any such persons develop symptoms before seven days, they must betested immediately.
states may, however, take additional steps as per local requirements.
Yours sincerel.v,
(Rajesh Bhushan)
To rChief Secretaries/Administrators of all States/UTs